Personal Pharma Resourcing Ltd 08596965 false 2024-08-01 2025-07-31 2025-07-31 The principal activity of the company is retail in medical and pharmaceutical goods as well as cosmetics and toiletries. Digita Accounts Production Advanced 6.30.9574.0 true true 08596965 2024-08-01 2025-07-31 08596965 2025-07-31 08596965 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2025-07-31 08596965 bus:OrdinaryShareClass2 bus:Non-cumulativeShares 2025-07-31 08596965 core:RetainedEarningsAccumulatedLosses 2025-07-31 08596965 core:ShareCapital 2025-07-31 08596965 core:CurrentFinancialInstruments 2025-07-31 08596965 core:CurrentFinancialInstruments core:WithinOneYear 2025-07-31 08596965 core:Non-currentFinancialInstruments 2025-07-31 08596965 core:Non-currentFinancialInstruments core:AfterOneYear 2025-07-31 08596965 core:OtherRelatedParties 2025-07-31 08596965 bus:SmallEntities 2024-08-01 2025-07-31 08596965 bus:AuditExemptWithAccountantsReport 2024-08-01 2025-07-31 08596965 bus:FilletedAccounts 2024-08-01 2025-07-31 08596965 bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 08596965 bus:RegisteredOffice 2024-08-01 2025-07-31 08596965 bus:Director1 2024-08-01 2025-07-31 08596965 bus:Director2 2024-08-01 2025-07-31 08596965 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-08-01 2025-07-31 08596965 bus:OrdinaryShareClass2 bus:Non-cumulativeShares 2024-08-01 2025-07-31 08596965 bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 08596965 core:OtherRelatedParties 2024-08-01 2025-07-31 08596965 countries:England 2024-08-01 2025-07-31 08596965 2024-07-31 08596965 core:OtherRelatedParties 2024-07-31 08596965 2023-08-01 2024-07-31 08596965 2024-07-31 08596965 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-07-31 08596965 bus:OrdinaryShareClass2 bus:Non-cumulativeShares 2024-07-31 08596965 core:RetainedEarningsAccumulatedLosses 2024-07-31 08596965 core:ShareCapital 2024-07-31 08596965 core:CurrentFinancialInstruments 2024-07-31 08596965 core:CurrentFinancialInstruments core:WithinOneYear 2024-07-31 08596965 core:Non-currentFinancialInstruments 2024-07-31 08596965 core:Non-currentFinancialInstruments core:AfterOneYear 2024-07-31 08596965 core:OtherRelatedParties 2024-07-31 08596965 core:OtherRelatedParties 2023-08-01 2024-07-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 08596965

Personal Pharma Resourcing Ltd
Unaudited Filleted Financial Statements
for the Year Ended 31 July 2025

Personal Pharma Resourcing Ltd

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Unaudited Financial Statements | 3 to 7

Personal Pharma Resourcing Ltd

Company Information

Directors | Mr Oliver Hook Mrs Begum Erguven Hook

Registered office | 50 Bridgefield Farnham GU9 8AW

Accountants | Clever Accounts Limited Brookfield Court Selby Road Leeds LS25 1NB

Personal Pharma Resourcing Ltd

(Registration number: 08596965)
Balance Sheet as at 31 July 2025

| Note | 2025 £ | 2024 £
Current assets |  |  |
Debtors | 4 | 10,547 | 3,615
Cash at bank and in hand |  | 14,602 | 14,330
|  | 25,149 | 17,945
Creditors: Amounts falling due within one year | 5 | (6,035) | (5,222)
Total assets less current liabilities |  | 19,114 | 12,723
Creditors: Amounts falling due after more than one year | 5 | (11,530) | (13,878)
Net assets/(liabilities) |  | 7,584 | (1,155)
Capital and reserves |  |  |
Called up share capital | 6 | 2 | 2
Retained earnings |  | 7,582 | (1,157)
Shareholders' funds/(deficit) |  | 7,584 | (1,155)

For the financial year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 26 January 2026 and signed on its behalf by:

.........................................

Mr Oliver Hook
Director

Personal Pharma Resourcing Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

1 | General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
50 Bridgefield
Farnham
GU9 8AW

These financial statements were authorised for issue by the Board on 26 January 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Personal Pharma Resourcing Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Personal Pharma Resourcing Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2024 - 2).

4 | Debtors

Current | 2025 £ | 2024 £
Trade debtors | 10,547 | -
Other debtors | - | 3,615
| 10,547 | 3,615

Personal Pharma Resourcing Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

5 | Creditors

Creditors: amounts falling due within one year

| 2025 £ | 2024 £
Due within one year |  |
Taxation and social security | 5,689 | 5,188
Accruals and deferred income | 34 | 34
Other creditors | 312 | -
| 6,035 | 5,222

Creditors: amounts falling due after more than one year

| Note | 2025 £ | 2024 £
Due after one year |  |  |
Loans and borrowings | 7 | 11,530 | 13,878

6 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary of £1 each | 1 | 1 | 1 | 1
Ordinary A of £1 each | 1 | 1 | 1 | 1
| 2 | 2 | 2 | 2

7 | Loans and borrowings

Non-current loans and borrowings

| 2025 £ | 2024 £
Bank borrowings | 11,530 | 13,878

8 | Related party transactions

Personal Pharma Resourcing Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Loans to related parties

2025 | Other related parties £ | Total £
At start of period | 3,615 | 3,615
Repaid | (3,615) | (3,615)
At end of period | - | -

2024 | Other related parties £ | Total £
Advanced | 3,615 | 3,615
At end of period | 3,615 | 3,615

Terms of loans to related parties

Included in other debtors is an advance loan due by the director of the company of nil (2024: £3,615l)
The loan was interest free and repayable on demand.